Welcome to our dedicated page for BIORA THERAPEUTICS SEC filings (Ticker: BIOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biora Therapeutics, historically associated with the ticker BIOR, has communicated key developments through regulatory and legal processes described in its public news releases. Although specific SEC forms are not listed here, company announcements provide insight into events that would typically be reflected in formal filings, including financing activities, listing status on Nasdaq, and a chapter 11 process in the District of Delaware.
In a release dated December 30, 2024, Biora stated that it had filed a voluntary petition under chapter 11 of the U.S. Bankruptcy Code in the District of Delaware. The company explained that this court-supervised sale process was supported by a debtor in possession financing facility agreed with certain prepetition creditors, with those lenders serving as a stalking horse bidder for the company’s assets. This type of event is usually documented in bankruptcy court filings and related disclosures.
Later, on March 31, 2025, Biora announced the successful completion of its restructuring, stating that it had emerged as a privately held company with an improved balance sheet and new long-term financing. The same announcement notes that ownership of the company transitioned to certain lenders and that the company’s existing common shares were cancelled pursuant to a Plan of Reorganization. Such developments are typically accompanied by court orders and, when a company is publicly traded, by SEC filings describing the restructuring and its impact on equity holders.
Earlier news items also reference Nasdaq listing compliance matters and registered direct offerings under a shelf registration statement on Form S-3, indicating that Biora filed offering documents and prospectus supplements with the SEC in connection with equity financings and warrant amendments. While this page does not enumerate individual forms such as 10-K, 10-Q, or Form 4, investors researching BIOR’s history can use these public statements as a guide to the types of regulatory and court filings that have documented Biora Therapeutics’ capital structure, listing status, and transition from a public to a privately held company.
On Stock Titan, BIOR-related filings, where available, can be paired with AI-driven summaries to help explain complex restructuring steps, financing terms, and historical disclosure around the NaviCap and BioJet platforms as reported in the company’s public documents.
Biora Therapeutics, Inc. (BIOR) – Schedule 13G/A Amendment No. 1
Context Capital Management, LLC, together with four related reporting persons (Michael S. Rosen, William D. Fertig, Charles E. Carnegie and Context Partners Master Fund, L.P.), has filed an amended Schedule 13G reporting beneficial ownership of 22,025 BIOR common shares as of 30 June 2025. The filing cites an outstanding share count of 4,522,702 (as of 6 Nov 2024), placing the group’s holding at 0.5 % of the company’s common equity.
- Sole voting/dispositive power: 0 shares
- Shared voting/dispositive power: 22,025 shares
- Filing basis: Passive ownership; certifications state the position was acquired in the ordinary course and not for the purpose of influencing control.
- Reporting structure: LLC is general partner and investment adviser to the Cayman-domiciled master fund; the three individuals are control persons of the LLC. All parties disclaim membership in a group and beneficial ownership except for pecuniary interest.
- Ownership status: Item 5 confirms ownership of <5 % of the class; therefore the position is below the threshold that typically triggers Schedule 13D obligations.
The amendment does not disclose purchase dates, cost basis, or any intention to alter the company’s strategy. Given the <0.5 % stake, the filing is primarily informative and is unlikely to be a market-moving catalyst on its own.